In preclinical studies, combination treatment with a nucleotide-derivative AKT inhibitor significantly enhanced the antiproliferative activity of an anti-HER2 antibody in breast cancer xenograft models, while combination treatment with a rapamycin-derivative mTOR inhibitor did not45. The gene discussed is AKT1; the disease is breast carcinoma.